Forné M, Domínguez J, Fernández-Bañares F, Lite J, Esteve M, Galí N, Espinós J C, Quintana S, Viver J M
Department of Gastroenterology, Hospital Universitari Mútua de Terrassa, Barcelona, Spain.
Am J Gastroenterol. 2000 Sep;95(9):2200-5. doi: 10.1111/j.1572-0241.2000.02303.x.
The aim of this study was to assess the reliability of a newly developed enzyme immunoassay for Helicobacter pylori-specific antigen detection in stools (HpSA) compared to other standardized diagnostic techniques such as histology (H), rapid urease test (RUT) and 13C-urea breath test (UBT) to diagnose H. pylori infection and to evaluate its usefulness in determining H. pylori status after treatment.
One hundred eighty-eight patients referred to our department for upper gastrointestinal endoscopy were included. H. pylori infection was confirmed in all patients by HpSA test in stools, RUT, UBT, and H. Patients were defined as positive for H. pylori if RUT and UBT or H were positive. A total of 142 symptomatic patients received eradication treatment and were reassessed 6 wk after therapy; for 70 of these patients, stool samples were also collected at 24 h and 6 months after finishing eradication treatment. In the posttreatment follow-up, UBT was used as gold standard.
The sensitivity of HpSA test for the diagnosis of H. pylori infection using a cut-off value of 0.130 was 89.5% and its specificity 77.8%. This specificity was lower than that obtained with UBT, H, and RUT. In the early follow-up the sensitivity of HpSA test was null. At 6 weeks and at 6 months post-treatment its sensitivity was 70.4% and 50% and its specificity was 81.6% and 79.3%, respectively.
The HpSA stool test, using a cut-off value of 0.130, may be useful for the primary diagnosis of H. pylori infection, with sensitivity similar to that obtained with other standard tests, but with less specificity. HpSA test is not useful for early monitoring of treatment efficacy. At 6 wk and at 6 months posttreatment, HpSA test lacks accuracy as compared to UBT for evaluating the outcome of the eradication treatment.
本研究旨在评估一种新开发的用于检测粪便中幽门螺杆菌特异性抗原(HpSA)的酶免疫测定法与其他标准化诊断技术(如组织学检查(H)、快速尿素酶试验(RUT)和13C-尿素呼气试验(UBT))相比,在诊断幽门螺杆菌感染方面的可靠性,并评估其在确定治疗后幽门螺杆菌感染状况中的作用。
纳入188例因上消化道内镜检查转诊至我科的患者。通过粪便HpSA检测、RUT、UBT和组织学检查确诊所有患者是否感染幽门螺杆菌。若RUT和UBT或组织学检查结果为阳性,则患者被定义为幽门螺杆菌感染阳性。共有142例有症状的患者接受了根除治疗,并在治疗后6周进行重新评估;其中70例患者在完成根除治疗后的24小时和6个月也采集了粪便样本。在治疗后的随访中,UBT被用作金标准。
采用截断值0.130时,HpSA检测诊断幽门螺杆菌感染的敏感性为89.5%,特异性为77.8%。该特异性低于UBT、组织学检查和RUT的特异性。在早期随访中,HpSA检测的敏感性为零。治疗后6周和6个月时,其敏感性分别为70.4%和50%,特异性分别为81.6%和79.3%。
采用截断值0.130的粪便HpSA检测可能有助于幽门螺杆菌感染的初步诊断,其敏感性与其他标准检测相似,但特异性较低。HpSA检测对治疗效果的早期监测无用。与UBT相比,治疗后6周和6个月时,HpSA检测在评估根除治疗效果方面缺乏准确性。